Open AccessPrevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review
Author(s) -
Kevin Winthrop,
Yoshiya Tanaka,
Eun Bong Lee,
J. Wollenhaupt,
Ahmad Al Enizi,
Valderílio Feijó Azevedo,
Jeffrey R. Curtis
Publication year - 2022
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/cpu6r9
Subject(s) - medicine , psoriatic arthritis , rheumatoid arthritis , vaccination , immunogenicity , population , immunology , intensive care medicine , dermatology , immune system , environmental health
The risk of herpes zoster (HZ) and HZ-related complications is increased in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) relative to the general population; therefore, HZ vaccination is recommended in these patient groups. In this literature-based review, we summarise the available evidence on the use of HZ vaccines in patients with RA and PsA, and discuss strategies for managing breakthrough infection. Currently available data show suboptimal rates of HZ vaccination among these patients and highlight a need for strategies to improve HZ vaccination programmes in clinical practice. Further clinical studies are also required to optimise the use of HZ vaccines in patients with RA and PsA, particularly with regard to determining the impact of different immunosuppressive therapy regimens on vaccine immunogenicity and, ultimately, efficacy, as well as the impact of vaccination on disease activity and safety.